Tissue Factor-Activated Coagulation Cascade in the Tumor Microenvironment Is Critical for Tumor Progression and an Effective Target for Therapy

被引:77
作者
Liu, Yuan [1 ]
Jiang, Pengfei [1 ]
Capkova, Katerina [2 ]
Xue, Dong [1 ]
Ye, Longwu [1 ]
Sinha, Subhash C. [3 ]
Mackman, Nigel [4 ]
Janda, Kim D. [2 ]
Liu, Cheng [1 ]
机构
[1] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[4] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA
关键词
FACTOR CYTOPLASMIC DOMAIN; FACTOR EXPRESSION; COLORECTAL-CANCER; PRODRUG THERAPY; CATHEPSIN-B; FACTOR VIIA; ANGIOGENESIS; CELLS; DOXORUBICIN; INHIBITION;
D O I
10.1158/0008-5472.CAN-11-1145
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tissue factor (TF), a rate-limiting enzyme cofactor in activating coagulation, is highly expressed in a wide spectrum of human tumor and tumor stromal cells. Using TF-deficient cancer cells and a conditional TF-knockout mouse model, we show that TF expressed by cancer cells, but not by the host stromal cells, plays a critical role in tumor growth. In the tumor microenvironment, serum coagulation factors are readily extravasated and therefore lead to continuous TF-mediated activation of coagulation proteases. To target this highly specific cascade of serine proteases, we used both a TF: VIIa inhibitor and doxorubicin-based prodrugs that are selectively activated by TF: FVIIa, FXa, and thrombin. Treatment with the TF: FVIIa inhibitor led to growth retardation in breast tumor models. In contrast, treatment with the prodrug eliminated primary tumor cells and lung metastases without apparent toxicity. Our findings offer preclinical proof of principle that targeting the coagulation cascade that is activated in the tumor microenvironment can be a highly effective approach for cancer therapy. Cancer Res; 71(20); 6492-502. (C) 2011 AACR.
引用
收藏
页码:6492 / 6502
页数:11
相关论文
共 44 条
[1]   Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia [J].
Ahamed, Jasimuddin ;
Niessen, Frank ;
Kurokawa, Toru ;
Lee, Young Kyung ;
Bhattacharjee, Gourab ;
Morrissey, James H. ;
Ruf, Wolfram .
BLOOD, 2007, 109 (12) :5251-5259
[2]   Tissue factor expression and prognosis in patients with metastatic prostate cancer [J].
Akashi, T ;
Furuya, Y ;
Ohta, S ;
Fuse, H .
UROLOGY, 2003, 62 (06) :1078-1082
[3]  
BAUER KA, 1990, BLOOD, V76, P731
[4]   WKS MOTIFS AND THE CYTOKINE RECEPTOR FRAMEWORK OF TISSUE FACTOR [J].
BAZAN, JF .
TRENDS IN BIOCHEMICAL SCIENCES, 1991, 16 (09) :329-329
[5]   Regulation of angiogenesis by tissue factor cytoplasmic domain signaling [J].
Belting, M ;
Dorrell, MI ;
Sandgren, S ;
Aguilar, E ;
Ahamed, J ;
Dorfleutner, A ;
Carmeliet, P ;
Mueller, BM ;
Friedlander, M ;
Ruf, W .
NATURE MEDICINE, 2004, 10 (05) :502-509
[6]  
Butenas S, 1997, THROMB HAEMOSTASIS, V78, P1193
[7]   PLASMIN-ACTIVATED PRODRUGS FOR CANCER-CHEMOTHERAPY .2. SYNTHESIS AND BIOLOGICAL-ACTIVITY OF PEPTIDYL DERIVATIVES OF DOXORUBICIN [J].
CHAKRAVARTY, PK ;
CARL, PL ;
WEBER, MJ ;
KATZENELLENBOGEN, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 1983, 26 (05) :638-644
[8]   In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant [J].
Combes, V ;
Simon, AC ;
Grau, GE ;
Arnoux, D ;
Camoin, L ;
Sabatier, F ;
Mutin, M ;
Sanmarco, M ;
Sampol, J ;
Dignat-George, F .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (01) :93-102
[9]   THE COAGULATION CASCADE - INITIATION, MAINTENANCE, AND REGULATION [J].
DAVIE, EW ;
FUJIKAWA, K ;
KISIEL, W .
BIOCHEMISTRY, 1991, 30 (43) :10363-10370
[10]   Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin [J].
de Groot, FMH ;
de Bart, ACW ;
Verheijen, JH ;
Scheeren, HW .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) :5277-5283